Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Retained Earnings (2019 - 2026)

C4 Therapeutics has reported Retained Earnings over the past 8 years, most recently at -$763.8 million for Q1 2026.

  • For Q1 2026, Retained Earnings fell 15.73% year-over-year to -$763.8 million; the TTM value through Mar 2026 reached -$763.8 million, down 15.73%, while the annual FY2025 figure was -$738.7 million, 1393860.38% down from the prior year.
  • Retained Earnings for Q1 2026 was -$763.8 million at C4 Therapeutics, down from -$738.7 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $53000.0 in Q4 2024 and troughed at -$763.8 million in Q1 2026.
  • A 5-year average of -$332.7 million and a median of -$358.7 million in 2022 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: surged 100.01% in 2024 and later crashed 1393860.38% in 2025.
  • Year by year, Retained Earnings stood at -$395.9 million in 2022, then tumbled by 33.47% to -$528.4 million in 2023, then surged by 100.01% to $53000.0 in 2024, then crashed by 1393860.38% to -$738.7 million in 2025, then dropped by 3.4% to -$763.8 million in 2026.
  • Business Quant data shows Retained Earnings for CCCC at -$763.8 million in Q1 2026, -$738.7 million in Q4 2025, and -$718.2 million in Q3 2025.